Biosergen AB (8N10) Price & Analysis

1 Followers

8N10 Stock Chart & Stats

€0.04

€0.00(0.00%)

Oct 27, 2026

―

Day’s Range― - ―

52-Week Range€0.04 - €0.55

Previous CloseN/A

VolumeN/A

Average Volume (3M)0.00

Market Cap

€3.69M

Enterprise Value€77.44M

Total Cash (Recent Filing)€3.23M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)―

Beta4.93

Next Earnings

Nov 18, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-5.61

Shares Outstanding82,684,270

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio-0.18

Price to Book (P/B)72.03

Price to Sales (P/S)0.00

P/FCF Ratio-23.02

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.1

Revenue Forecast (FY)€125.98K

Bulls Say, Bears Say

Bulls Say

Debt-Free Capital StructureThe absence of financial debt lowers fixed repayment obligations and reduces solvency pressure while the company advances its development program. This provides more financial flexibility than a similarly loss-making business carrying substantial leverage, although funding needs remain important.

Targeted Antifungal ProgramBSG005 addresses serious fungal infections with a lung-targeted delivery concept designed to reduce the systemic toxicity associated with conventional amphotericin B. If development succeeds, this differentiated therapeutic focus could support clinical utility and product positioning.

Improving Loss TrendThe reduction in net loss from 2025 to the latest trailing period indicates some improvement in reported earnings performance, even though the company remains deeply unprofitable. Sustaining this trend could gradually reduce the scale of future funding requirements and operating losses.

Bears Say

No Visible Revenue BaseEffectively zero revenue means the company has not yet demonstrated a commercial income stream in the reported periods. This leaves the business dependent on successful development and eventual commercialization of its program, with no established operating revenue to support ongoing costs.

Persistent Cash BurnConsistently negative operating and free cash flow shows that operations consume substantial cash rather than funding themselves. Continued burn reduces financial runway and requires external funding to sustain development, making capital access a durable determinant of execution capacity.

Shrinking Equity BaseThe sharp contraction in equity indicates substantial cumulative burn and/or dilution effects, leaving a much thinner capital base. This weakens financial resilience, increases dependence on future external funding, and can constrain the company’s ability to absorb setbacks or finance development.

8N10 FAQ

What was Biosergen AB’s price range in the past 12 months?

Biosergen AB lowest stock price was €0.04 and its highest was €0.55 in the past 12 months.

What is Biosergen AB’s market cap?

Biosergen AB’s market cap is €3.69M.

When is Biosergen AB’s upcoming earnings report date?

Biosergen AB’s upcoming earnings report date is Nov 18, 2026 which is in 18 days.

How were Biosergen AB’s earnings last quarter?

Biosergen AB released its earnings results on Feb 10, 2026. The company reported -€0.052 earnings per share for the quarter.

Is Biosergen AB overvalued?

According to Wall Street analysts Biosergen AB’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Biosergen AB pay dividends?

Biosergen AB does not currently pay dividends.

What is Biosergen AB’s EPS estimate?

Biosergen AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Biosergen AB have?

Biosergen AB has 82,684,270 shares outstanding.

What happened to Biosergen AB’s price movement after its last earnings report?

Biosergen AB reported an EPS of -€0.052 in its last earnings report. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Biosergen AB?

Currently, no hedge funds are holding shares in DE:8N10

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Biosergen AB

Biosergen AB is a biopharmaceutical company specializing in the creation of antifungal medications. Its key development initiative is BSG005, an experimental antifungal drug candidate engineered to treat critical invasive fungal infections. The firm was established in 2004 and operates from its headquarters located in Solna, Sweden.